Li Zuyun, Xie You, Zhong Tengfei, Zhang Xiuling, Dang Yiwu, Gan Tingqing, Chen Gang
Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
J BUON. 2015 Jul-Aug;20(4):1101-6.
MAS-related G protein-coupled receptor, member D (MRGD) has been reported to be involved in tumorigenesis in vivo. However, the clinical role of MRGD in non-small cell lung cancer (NSCLC) remains unclarified. The purpose of the current study was to detect the expression of MRGD mRNA in NSCLC formalin-fixed (FF), paraffin-embedded (PE) tissues and to investigate the clinicopathological significance of the MRGD level in NSCLC patients.
The expression of MRGD mRNA was examined in 125 NSCLC tissue samples together with paired para-noncancerous FF/PE tissues by using real time quantitative PCR (qRT-PCR). Furthermore, the relationship between MRGD level and clinicopathological parameters of NSCLC was analyzed.
The average level of MRGD in NSCLC tumor tissues (1.0682±0.6096) was remarkably higher than that in the adjacent non-cancerous lung tissue (0.3994±0.2838, p<0.001). The area under curve (AUC) of receiver operating characteristic curve (ROC) of MRGD mRNA was 0.853 (95% CI: 0.808-0.898, p(0.001). Moreover, the level of MRGD mRNA was found to be correlated to lymph node metastasis (r=0.219, p=0.014), tumor size (r=0.221, p=0.013) and clinical TNM stage (r=0.187, p=0.037). Finally, the survival of patients in high MGRD expression group was 7.94±9.85 months, remarkably shorter than that of the low expression group (20.84±1.19 months, p=0.049).
MRGD may be a vital diagnostic and prognostic factor in NSCLC. MRGD possesses the potential to become a new target for the molecular therapy of NSCLC.
据报道，MAS相关G蛋白偶联受体D成员（MRGD）参与体内肿瘤发生。然而，MRGD在非小细胞肺癌（NSCLC）中的临床作用仍不明确。本研究的目的是检测MRGD mRNA在NSCLC福尔马林固定（FF）、石蜡包埋（PE）组织中的表达，并探讨MRGD水平在NSCLC患者中的临床病理意义。
采用实时定量PCR（qRT-PCR）检测125例NSCLC组织样本及配对的癌旁FF/PE组织中MRGD mRNA的表达。此外，分析了MRGD水平与NSCLC临床病理参数之间的关系。
NSCLC肿瘤组织中MRGD的平均水平（1.0682±0.6096）显著高于相邻的非癌肺组织（0.3994±0.2838，p<0.001）。MRGD mRNA的受试者工作特征曲线（ROC）的曲线下面积（AUC）为0.853（95%CI：0.808-0.898，p<0.001）。此外，发现MRGD mRNA水平与淋巴结转移（r=0.219，p=0.014）、肿瘤大小（r=0.221，p=0.013）和临床TNM分期（r=0.187，p=0.037）相关。最后，高MGRD表达组患者的生存期为7.94±9.85个月，显著短于低表达组（20.84±1.19个月，p=0.049）。
MRGD可能是NSCLC的一个重要诊断和预后因素。MRGD有潜力成为NSCLC分子治疗的新靶点。
